Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CHS 114 (Primary) ; Toripalimab (Primary)
  • Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 03 Dec 2024 According to a Coherus BioSciences media release, phase 1 dose escalation is complete. Phase 1 monotherapy biopsy data as well as CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) expected in 1H 2025.
    • 06 Nov 2024 According to a Coherus BioSciences media release, the company expects to report Phase 1 data from expansion cohorts in the first half of 2025.
    • 08 Aug 2024 According to a Coherus BioSciences media release, the decrease in R&D expenses in Q2 and 1H in 2024 compared to Q2 and 1H in 2023, was balanced by increased costs for development of casdozokitug and CHS-114.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top